previous Menu

previous

CA 19-9 (Roche: ECLIA) (Serum (s))

Testcode:	E_CA199R
Specimens:	500 µl Serum (s)
Preanalytics/Notes:	In patients receiving therapy with high biotin doses (i.e. > 5 mg/day) no sample should be taken until at least 8 hours after the last biotin administration, as high dosis biotin application might disturbe the assay. Please note: results obtained using different methods and/or test manufacturers cannot be compared with one another. The course of tumor markers should always be assessed by the same test.
Method:	ECLIA
Dimension:	U/ml
Set-up:	Mon Tue Wed Thu Fri Sat Sun
Duration:	1 day
Indication/Significance:	Tumour marker in the case of suspected pancreatic carcinoma (highest sensitivity) Tumour screening in the case of suspected gastro-intestinal tumours together with other tumour markers Follow up during therapy, diagnosis and follow up in the case of colorectal carcinomas (second marker after CEA) and ovarian carcinoma (second marker after CA 125)
Interpretation:	CA 19-9 cannot be more… CA 19-9 cannot be detected in patients with the rare blood type Lewis a/b negative (approx. 5 % of the population). Alternatively, the marker CA 50 can be used. CA 19-9 is a marker of first choice for the diagnosis, therapy control and prognostic assessment of pancreatic carcinoma (sensitivity up to 95 %) as well as for the therapy control of cholangiocarcinoma; it is the marker of second choice for colorectal carcinoma (after CEA), ovarian carcinoma (after CA 125) and gastric carcinoma (after 72-4). Like the most tumour markers, CA 19-9 is not specific for the mentioned carcinomas. With benign diseases, increased levels are found comparable seldom, at most in the case of choledocholithiasis, cholecystitis and chronic liver diseases. Levels above 200 U/ml can only rarely be detected in benign diseases. The biological half-life is 4 - 8 days. The additional determination of CA 50 does not have a diagnostic benefit as it is a preliminary stage of CA 19-9 (indicated in patients with the rare blood group Lewis a/b negative). see table under keyword "tumour marker" close
Further tests:	CEA

performance by Bioscientia medical service centers

Reference range / valuation (openclose)

both sex
	< 34 U/ml

initial letter

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Close

Abrechnung GOÄ

Die Kosten werden für den i. d. R. genutzten 1,15-fachen GOÄ-Satz dargestellt. Wird die Untersuchung nicht in Ihrem regionalen Labor durchgeführt, erfolgt die Analyse in dem Labor, das im Leistungsverzeichnis genannt ist. In diesem Fall gilt der dort für die Untersuchung angegebene Preis.